Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation - PubMed

Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation - PubMed

Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation

Paul J Martin 1 2, David M Levine 3, Barry E Storer 1, Sarah C Nelson 3, Xinyuan Dong 3, John A Hansen 1 2

Affiliations 

• PMID: 32687560
 
• DOI: 10.1182/bloodadvances.2020001927

Abstract

Many studies have suggested that genetic variants in donors and recipients are associated with survival-related outcomes after allogeneic hematopoietic cell transplantation (HCT), but these results have not been confirmed. Therefore, the utility of testing genetic variants in donors and recipients for risk stratification or understanding mechanisms leading to mortality after HCT has not been established. We tested 122 recipient and donor candidate variants for association with nonrelapse mortality (NRM) and relapse mortality (RM) in a cohort of 2560 HCT recipients of European ancestry with related or unrelated donors. Associations discovered in this cohort were tested for replication in a separate cohort of 1710 HCT recipients. We found that the donor rs1051792 A allele in MICA was associated with a lower risk of NRM. Donor and recipient rs1051792 genotypes were highly correlated, making it statistically impossible to determine whether the donor or recipient genotype accounted for the association. Risks of grade 3 to 4 graft-versus-host disease (GVHD) and NRM in patients with grades 3 to 4 GVHD were lower with donor MICA-129Met but not with MICA-129Val, implicating MICA-129Met in the donor as an explanation for the decreased risk of NRM after HCT. Our analysis of candidate variants did not show any other association with NRM or RM. A genome-wide association study did not identify any other variants associated with NRM or RM.

© 2020 by The American Society of Hematology.

Similar articles

• Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.

  Faridi RM, Kemp TJ, Dharmani-Khan P, Lewis V, Tripathi G, Rajalingam R, Daly A, Berka N, Storek J, Masood Khan F.PLoS One. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242. eCollection 2016.PMID: 27341514 Free PMC article.
• Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.

  Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM.Biol Blood Marrow Transplant. 2020 Jul;26(7):1312-1317. doi: 10.1016/j.bbmt.2020.04.001. Epub 2020 Apr 10.PMID: 32283185 Free PMC article.
• Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.

  Rezvani AR, Storer BE, Guthrie KA, Schoch HG, Maloney DG, Sandmaier BM, Storb R.Biol Blood Marrow Transplant. 2015 Jan;21(1):105-12. doi: 10.1016/j.bbmt.2014.09.021. Epub 2014 Sep 30.PMID: 25278458 Free PMC article.
• MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study.

  Askar M, Sobecks R, Wang T, Haagenson M, Majhail N, Madbouly A, Thomas D, Zhang A, Fleischhauer K, Hsu K, Verneris M, Lee SJ, Spellman SR, Fernández-Viña M.Biol Blood Marrow Transplant. 2017 Mar;23(3):436-444. doi: 10.1016/j.bbmt.2016.11.021. Epub 2016 Dec 14.PMID: 27987385 Free PMC article. Clinical Trial.
• Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

  Petersen SL.Dan Med Bull. 2007 May;54(2):112-39.PMID: 17521527 Review.